ArticleFrontiers in cellular neuroscience2022
Role of Dectin-1 in peripheral nerve injury.
Article in Frontiers in cellular neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- Role of transforming growth factor-β in peripheral nerve regeneration.Neural regeneration research · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dectin-1, a C-type lectin receptor, plays a role in nerve injury in the central nervous system. However, whether it plays a role in the peripheral nervous system is not well understood. Our study showed the expression of Dectin-1 on the membrane of macrophages. We also used a sciatic nerve crushing injury model to demonstrate that there was a delay in nerve degeneration-related processes such as breakdown of injured myelinated nerve fibers and formation of myelin ovoid in groups injected with whole glucan particle soluble (WGPS), a Dectin-1 antagonist. There were also fewer intraneural blood vessels in the Dectin-1 antagonist treated group. Our study suggested inhibiting Dectin-1 delayed debris clearance, nerve degeneration, and angiogenesis after peripheral nerve injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.